Startups in the wide-ranging Australian healthtech sector have raised more than a combined $165 million in funding, while biotech sits at $87.8 million.
Between bone repair glue and gene splicing, there is a diverse range of startups working to improve our health or innovate the way the sector operates.
Trimph is a biomedical startup working to commercialise a range of medical technologies using their patented polymer platform.
The government has launched the Biomedical Translation Fund, a $500 million fund that will help commercialise biomedical discoveries.
After receiving a $1 million grant through the Federal Government’s Accelerating Commercialisation program earlier this year, biotech company Clarity Pharmaceuticals has announced it has raised a further $2 million in funding to help further develop its technology.
Clinical Genomics, a biotechnology company working across the United States and Australia, has closed a US$15 million ($19.7 million) round led by Sydney-based VC firm OneVentures.